Medidata Successfully Hosts Annual European NEXT Conference Series
July 13 2017 - 5:30AM
Business Wire
Events Bring Together Industry Leaders to
Examine Technology’s role in Transforming Clinical
Development
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced the successful completion of the annual NEXT
Conference series in Europe during June 2017, with events having
occurred in Basel, Berlin and London. Each event brought together
leading industry experts to examine how data, insights and
technology are transforming the future of clinical trials and drug
development processes in a $4.0 billion global e-clinical
technology industry.1
Drawing upon Medidata’s experience in over 15 therapeutic areas,
Medidata’s senior management, including Co-Founders Tarek Sherif
(CEO and Chairman) and Glen de Vries (President) as well as Chief
Operating Officer, Mike Capone, presented how to unlock the value
of clinical trial data to accelerate drug development. Having
acknowledged the growing cost burden on healthcare systems driven
by ageing populations and high clinical failure rates, Medidata
demonstrated how its platforms are bringing innovation to
streamline the complete drug development process. Multiple partner
case studies demonstrated how the Medidata Clinical Cloud® platform
is powering the future of clinical trials with intelligent site
selection and risk based monitoring.
Guest speakers from Medidata’s customers included Louise Lampe,
Global Head of Central Data Science, at Boehringer Ingelheim; Steve
Nabarro, Head of Clinical Operations and Data Management at Cancer
Research UK; and Susan Griffing, VP Global Head Country Clinical
Operations at Roche. These speakers actively discussed the
challenges and complexity of drug development, while providing a
customer perspective on how Medidata’s technology is transforming
clinical trial practices, increasing efficiency and improving
patient outcomes. Industry experts and partners, including Petra
Jantzer, EALA Life Sciences R&D Lead at Accenture; Cornelia
Yzer, Former Berlin Senator and Secretary of State; and Bill Byrom,
Senior Director Product Innovation at ICON, provided perspective on
the industry today, the latest trends moving forward, and the realm
of possibility for clinical trials.
“Prior to each event there was a hackathon where individuals had
the opportunity to collaborate with fellow developers, designers
and system integration officers to create solutions to drug
development barriers in the clinical trial space,” explained Ross
Rothmeier, VP of technology solutions and innovation labs,
Medidata. “These hackathons demonstrated how leveraging technology,
such as virtual reality systems and Medidata’s RAVE application,
adds value by improving outcomes, increasing accuracy and
simplifying trials and accessibility.”
“Given the cost challenges the industry faces, long development
timelines and need to bring drugs to patients sooner, technologies
and services that expedite development are valuable. Bringing
scientists and other industry experts from across Europe into the
NEXT series provided a great opportunity to share expertise,
improve efficiency and strategize for the future.” said Rachel
Darby-Dowman of Cancer Research UK after London’s NEXT event.
“I am pleased with the success of the NEXT conference series
that brought together over 300 technology leaders and industry
experts to evaluate how technology is revolutionizing drug
development,” commented Christian Hebenstreit, General Manager
EMEA, Medidata. “The series provided an ideal platform for industry
experts to exchange ideas and share best practices of how to
utilize data and technology to effectively design, execute and
report better clinical trials on a global scale to accelerate drug
development and deliver important new treatment options to patients
around the world. We look forward to Medidata NEXT Global in New
York this November and to continue this important series throughout
Europe in 2018.”
Further details for the events can be found at
http://medidatanext.com/
1 Medidata Analysis
About Medidata NEXT
Medidata NEXT (formerly Medidata Symposium) began in 2006
when a group of dedicated Medidata customers collaborated to create
an open and mutually beneficial environment to network, exchange
ideas, share best practices and provide feedback to Medidata.
Today, Medidata NEXT has become an even more diverse
mix of global Medidata customers and service partners who enjoy the
benefits of the Medidata Clinical Cloud®. To date, nearly 40
conferences around the globe have gathered thousands of technology
users and clinical leaders.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, innovative biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 16 of the top
20 medical device developers— from study design and planning
through execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170713005175/en/
Investor:Medidata SolutionsAnthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Medidata SolutionsErik
Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024